Suppr超能文献

具有β-连环蛋白激活的非典型肝细胞腺瘤样肿瘤显示出与高分化肝细胞癌相似的细胞遗传学改变。

Atypical hepatocellular adenoma-like neoplasms with β-catenin activation show cytogenetic alterations similar to well-differentiated hepatocellular carcinomas.

机构信息

Department of Pathology and Liver Center, University of California, San Francisco, CA 94143, USA.

出版信息

Hum Pathol. 2013 May;44(5):750-8. doi: 10.1016/j.humpath.2012.07.019. Epub 2012 Oct 16.

Abstract

The distinction of hepatocellular adenoma from well-differentiated hepatocellular carcinoma (HCC) arising in noncirrhotic liver can be challenging, particularly when tumors histologically resembling hepatocellular adenoma occur in unusual clinical settings such as in a man or an older woman or show focal atypical morphologic features. In this study, we examine the morphologic, immunohistochemical, and cytogenetic features of hepatocellular adenoma-like neoplasms occurring in men, women 50 years or older or younger than 15 years, and/or those with focal atypia (small cell change, pseudogland formation, and/or nuclear atypia), designated atypical hepatocellular neoplasms, where the distinction of hepatocellular adenoma versus HCC could not be clearly established. Immunohistochemistry was performed for β-catenin, glutamine synthetase, and serum amyloid A in 31 hepatocellular adenomas, 20 well-differentiated HCCs, and 40 atypical hepatocellular neoplasms. Chromosomal gains/losses had previously been determined in 37 cases using comparative genomic hybridization or fluorescence in situ hybridization. β-Catenin activation was observed in 35% of atypical hepatocellular neoplasms compared with 10% of typical hepatocellular adenomas (P < .05) and 55% of well-differentiated HCCs (P = .14). Cytogenetic changes typically observed in HCC were present in all atypical hepatocellular neoplasms with β-catenin activation. β-Catenin activation in atypical hepatocellular neoplasms was also associated with atypical morphologic features. Follow-up data were limited, but adverse outcome was observed in 2 atypical hepatocellular neoplasms with β-catenin activation (1 recurrence, 1 metastasis); transition to areas of HCC was observed in 1 case. The similarity in morphologic and cytogenetic features of β-catenin-activated hepatocellular adenoma-like tumors and HCC suggests that the former tumors represent an extremely well-differentiated variant of HCC.

摘要

肝细胞腺瘤与非肝硬化肝脏中发生的高分化肝细胞癌(HCC)的鉴别具有挑战性,特别是当组织学上类似于肝细胞腺瘤的肿瘤发生在不常见的临床环境中,如男性或老年女性,或表现出局灶性非典型形态特征时。在这项研究中,我们检查了发生在男性、50 岁或以上或 15 岁以下的女性、和/或具有局灶性非典型性(小细胞改变、假腺形成和/或核异型性)的肝细胞腺瘤样肿瘤的形态学、免疫组织化学和细胞遗传学特征,将其指定为非典型肝细胞肿瘤,其中肝细胞腺瘤与 HCC 的鉴别不能明确确定。对 31 例肝细胞腺瘤、20 例高分化 HCC 和 40 例非典型肝细胞肿瘤进行了β-连环蛋白、谷氨酰胺合成酶和血清淀粉 A 的免疫组织化学检测。先前使用比较基因组杂交或荧光原位杂交在 37 例病例中确定了染色体获得/丢失。与 10%的典型肝细胞腺瘤(P<0.05)和 55%的高分化 HCC(P=0.14)相比,35%的非典型肝细胞肿瘤中观察到β-连环蛋白激活。在所有具有β-连环蛋白激活的非典型肝细胞肿瘤中均存在通常在 HCC 中观察到的细胞遗传学改变。β-连环蛋白激活的非典型肝细胞肿瘤也与非典型形态特征相关。随访数据有限,但在 2 例具有β-连环蛋白激活的非典型肝细胞肿瘤中观察到不良结局(1 例复发,1 例转移);在 1 例中观察到向 HCC 区域的转变。具有β-连环蛋白激活的肝细胞腺瘤样肿瘤与 HCC 在形态和细胞遗传学特征上的相似性表明,前者肿瘤代表 HCC 的一种极分化的变体。

相似文献

7
gene rearrangement: a powerful driver of β-catenin activation in liver tumours.
Gut. 2019 Jul;68(7):1287-1296. doi: 10.1136/gutjnl-2018-317632. Epub 2019 Feb 2.

引用本文的文献

1
High Frequency of Variants Associated with Benign and Malignant Liver Tumors in Patients with Congenital Porto-Systemic Shunts.
Liver Cancer. 2024 Dec 28;14(4):408-419. doi: 10.1159/000543217. eCollection 2025 Aug.
3
Exploring the Impact of the β-Catenin Mutations in Hepatocellular Carcinoma: An In-Depth Review.
Cancer Control. 2024 Jan-Dec;31:10732748241293680. doi: 10.1177/10732748241293680.
4
Current and Emerging Molecular Markers of Liver Diseases: A Pathogenic Perspective.
Gene Expr. 2022;21(1):9-19. doi: 10.14218/gejlr.2022.00010. Epub 2022 Sep 28.
5
Glutamine metabolic reprogramming in hepatocellular carcinoma.
Front Mol Biosci. 2023 Aug 11;10:1242059. doi: 10.3389/fmolb.2023.1242059. eCollection 2023.
6
Benign liver tumours: understanding molecular physiology to adapt clinical management.
Nat Rev Gastroenterol Hepatol. 2022 Nov;19(11):703-716. doi: 10.1038/s41575-022-00643-5. Epub 2022 Jul 14.
7
Hepatocellular adenoma in men: A nationwide assessment of pathology and correlation with clinical course.
Liver Int. 2021 Oct;41(10):2474-2484. doi: 10.1111/liv.14989. Epub 2021 Jul 8.
8
Hepatocellular adenomas: recent updates.
J Pathol Transl Med. 2021 May;55(3):171-180. doi: 10.4132/jptm.2021.02.27. Epub 2021 Apr 7.
9
Hepatocellular adenoma in the paediatric population: Molecular classification and clinical associations.
World J Gastroenterol. 2020 May 21;26(19):2294-2304. doi: 10.3748/wjg.v26.i19.2294.
10
Characteristics of atypical large well-differentiated hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma?
HPB (Oxford). 2020 Apr;22(4):545-552. doi: 10.1016/j.hpb.2019.08.012. Epub 2019 Sep 16.

本文引用的文献

1
Optimal management of hepatocellular carcinoma: challenges and opportunities.
J Gastroenterol Hepatol. 2010 Aug;25(8):1336-8. doi: 10.1111/j.1440-1746.2010.06373.x.
3
Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours.
Nature. 2009 Jan 8;457(7226):200-4. doi: 10.1038/nature07475. Epub 2008 Nov 19.
4
Over-expression of glutamine synthetase in focal nodular hyperplasia: a novel easy diagnostic tool in surgical pathology.
Liver Int. 2009 Mar;29(3):459-65. doi: 10.1111/j.1478-3231.2008.01849.x. Epub 2008 Sep 18.
5
Nuclear beta-catenin staining and absence of steatosis are indicators of hepatocellular adenomas with an increased risk of malignancy.
Histopathology. 2007 Dec;51(6):855-6. doi: 10.1111/j.1365-2559.2007.02862.x. Epub 2007 Sep 28.
7
WNT/beta-catenin signaling in liver health and disease.
Hepatology. 2007 May;45(5):1298-305. doi: 10.1002/hep.21651.
8
Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas.
Oncogene. 2007 Feb 1;26(5):774-80. doi: 10.1038/sj.onc.1209824. Epub 2006 Sep 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验